SingaporeOverview
Financial Performance
Revenue
Not Provided
Gross Profit
Not Provided
Net Profit
Not Provided
Monthly Rentalt
Not Provided
Business Operations & Assets
Staff
12 Employee
Year of Incorporation
2017
Owner Role
Investor
Premise Type
Work at Home
Business Details
Reason For Sale
Expansion
Description
What if you could hold ground-floor equity in the only real-world treatment proven to reverse the planet's leading cause of death?
• Multi-Billion-Dollar Market: Targeting an urgent global crisis with zero direct competition and years of head start.
• Proven Revenue Traction: Multi-millions in verified cash receipts already banked, driven entirely by repeat customer organic demand.
• Immediate Dividends by Christmas: 90%+ margins generate immediate cash flow. With automated production scaling rapidly, net profit dividends are targeted to start flowing directly to investors by Christmas 2026
• Massive Long-Term Cashout: We don't have to wait five years. With patent-pending exclusivity and verified clinical plaque regression, a multi-hundred-million-dollar buyout or strategic pharma acquisition could trigger at virtually any time—delivering an explosive 25x–100x capital cashout.
• Defensible Monopoly: Protected by foundational patent filings, proprietary compounding secrets, and six years of human clinical evidence.
Opportunities combining profit dividends starting by Christmas, an airtight clinical monopoly, and a life-changing buyout that could strike at any time don't come around every day.
Request a copy of our prospectus now.
• Multi-Billion-Dollar Market: Targeting an urgent global crisis with zero direct competition and years of head start.
• Proven Revenue Traction: Multi-millions in verified cash receipts already banked, driven entirely by repeat customer organic demand.
• Immediate Dividends by Christmas: 90%+ margins generate immediate cash flow. With automated production scaling rapidly, net profit dividends are targeted to start flowing directly to investors by Christmas 2026
• Massive Long-Term Cashout: We don't have to wait five years. With patent-pending exclusivity and verified clinical plaque regression, a multi-hundred-million-dollar buyout or strategic pharma acquisition could trigger at virtually any time—delivering an explosive 25x–100x capital cashout.
• Defensible Monopoly: Protected by foundational patent filings, proprietary compounding secrets, and six years of human clinical evidence.
Opportunities combining profit dividends starting by Christmas, an airtight clinical monopoly, and a life-changing buyout that could strike at any time don't come around every day.
Request a copy of our prospectus now.
Important Disclaimer
Listing information is provided by the listing provider or their representatives and has not been independently verified by our platform. Users should verify all information and conduct their own due diligence before making any decision, payment or commitment.
All communications, agreements, transactions, disputes and claims are solely between the relevant parties.
Learn how to avoid scams